Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MRK Stock Forecast 2025-2026
$99.72
Current Price
$249.08B
Market Cap
Buy 16
Hold 13
Sell 0
Wall St Analyst Ratings
Distance to MRK Price Targets
+39.4%
To High Target of $139.00
+5.3%
To Median Target of $105.00
-17.8%
To Low Target of $82.00
MRK Price Momentum
-2.1%
1 Week Change
+15.6%
1 Month Change
-3.3%
1 Year Change
+0.2%
Year-to-Date Change
-5.8%
From 52W High of $105.84
+36.0%
From 52W Low of $73.31
📊 TOP ANALYST CALLS
Did MRK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Merck is one of their latest high-conviction picks.
Latest MRK Stock Price Targets & Analyst Predictions
Based on our analysis of 38 Wall Street analysts, MRK has a bullish consensus with a median price target of $105.00 (ranging from $82.00 to $139.00). The overall analyst rating is Strong Buy (8.1/10). Currently trading at $99.72, the median forecast implies a 5.3% upside. This outlook is supported by 16 Buy, 13 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robyn Karnauskas at Truist Securities, projecting a 39.4% upside. Conversely, the most conservative target is provided by Matthew Harrison at Morgan Stanley, suggesting a 17.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRK Analyst Ratings
16
Buy
13
Hold
0
Sell
MRK Price Target Range
Low
$82.00
Average
$105.00
High
$139.00
Current: $99.72
Latest MRK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 4, 2025 | Scotiabank | Louise Chen | Sector Outperform | Maintains | $120.00 |
| Dec 2, 2025 | Goldman Sachs | Terence Flynn | Buy | Maintains | $120.00 |
| Nov 24, 2025 | Wells Fargo | Mohit Bansal | Overweight | Upgrade | $125.00 |
| Nov 18, 2025 | Deutsche Bank | James Shin | Hold | Maintains | $111.00 |
| Nov 3, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $100.00 |
| Oct 13, 2025 | Citigroup | Geoff Meacham | Neutral | Reinstates | $95.00 |
| Sep 17, 2025 | Berenberg | Luisa Hector | Hold | Downgrade | $90.00 |
| Jul 30, 2025 | Wells Fargo | Mohit Bansal | Equal-Weight | Maintains | $90.00 |
| Jul 10, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $98.00 |
| May 14, 2025 | Citigroup | Andrew Baum | Neutral | Downgrade | $84.00 |
| Apr 22, 2025 | Cantor Fitzgerald | Carter Gould | Neutral | Initiates | $85.00 |
| Apr 17, 2025 | Guggenheim | Vamil Divan | Buy | Reiterates | $115.00 |
| Feb 18, 2025 | Deutsche Bank | James Shin | Hold | Downgrade | $105.00 |
| Feb 12, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $115.00 |
| Feb 5, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $106.00 |
| Feb 5, 2025 | BMO Capital | Evan David Seigerman | Market Perform | Maintains | $96.00 |
| Feb 5, 2025 | B of A Securities | Tim Anderson | Buy | Maintains | $112.00 |
| Feb 5, 2025 | Citigroup | Andrew Baum | Buy | Maintains | $115.00 |
| Jan 28, 2025 | Citigroup | Andrew Baum | Buy | Maintains | $125.00 |
| Jan 21, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $113.00 |
Merck & Co., Inc. (MRK) Competitors
The following stocks are similar to Merck based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Merck & Co., Inc. (MRK) Financial Data
Merck & Co., Inc. has a market capitalization of $249.08B with a P/E ratio of 13.2x. The company generates $64.23B in trailing twelve-month revenue with a 29.6% profit margin.
Revenue growth is +3.7% quarter-over-quarter, while maintaining an operating margin of +40.8% and return on equity of +39.5%.
Valuation Metrics
Market Cap
$249.08B
Enterprise Value
$270.72B
P/E Ratio
13.2x
PEG Ratio
0.2x
Price/Sales
3.9x
Growth & Margins
Revenue Growth (YoY)
+3.7%
Gross Margin
+77.7%
Operating Margin
+40.8%
Net Margin
+29.6%
EPS Growth
+83.2%
Financial Health
Cash/Price Ratio
+7.4%
Current Ratio
1.7x
Debt/Equity
79.7x
ROE
+39.5%
ROA
+13.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Merck & Co., Inc. (MRK) Business Model
About Merck & Co., Inc.
What They Do
Develops pharmaceuticals and vaccines for health solutions.
Business Model
The company generates revenue through the research, development, production, and marketing of innovative drugs and vaccines for various diseases affecting humans and animals. Key therapeutic areas include oncology, infectious diseases, and diabetes, with a focus on addressing critical health challenges globally.
Additional Information
Merck has a robust pipeline of new products and makes significant investments in research and development. It operates in multiple strategic regions, exporting advanced therapies to meet diverse healthcare needs. Additionally, Merck contributes to animal health by providing veterinary vaccines and services, enhancing agricultural productivity and food security.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
73,000
CEO
Mr. Robert M. Davis J.D.
Country
United States
IPO Year
1970
Website
www.merck.comMerck & Co., Inc. (MRK) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Can Merck's New Products Aid Growth as Keytruda LOE Test Looms?
MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.
Dec 04, 2025
By Zacks Equity Research
Analyst Blog
Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.
Dec 02, 2025
By Kinjel Shah
Analyst Blog
Why Merck (MRK) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Dec 02, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Merck's recent acquisition may facilitate the launch of a promising flu candidate, alongside other developments enhancing its prospects beyond Keytruda.
Why It Matters
Merck's acquisition may enhance its pipeline and revenue potential, signaling growth beyond Keytruda, which can boost investor confidence and stock valuation.
Source: The Motley Fool
Market Sentiment:
Positive
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
3 days ago
Quick Summary
U.S. advisory panel has removed its recommendation for infants to receive the hepatitis B vaccine at birth, raising concerns among vaccine makers and public health experts about potential setbacks in health progress.
Why It Matters
The decision may impact vaccine sales and revenues for manufacturers, raising concerns about future public health initiatives and potential liability, affecting investor confidence in the biotech sector.
Source: Reuters
Market Sentiment:
Negative
These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?
3 days ago
Quick Summary
Albemarle's lithium products are entering new markets, while Solventum, a recent spinoff from 3M, is establishing its presence.
Why It Matters
Albemarle's expansion into new lithium markets signals growth potential, while Solventum's stabilization post-spinoff may enhance investor confidence in 3M's overall value.
Source: The Motley Fool
Market Sentiment:
Neutral
Do These 3 Healthcare Stocks Need a Checkup?
3 days ago
Quick Summary
Pfizer offers a 6.8% yield, down nearly 60% from 2021 highs. Bristol Myers Squibb has a 5% yield, off about 40% from 2023 highs.
Why It Matters
Pfizer's high yield and significant decline may attract income-focused investors, while Bristol Myers Squibb's yield offers potential value. Both indicate potential buying opportunities amidst downturns.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
The article highlights five large-cap, dividend-paying companies with significant discounts to historical norms, offering yields from 3.6% to 8%.
Why It Matters
The focus on discounted, dividend-paying stocks signals potential value opportunities, appealing to investors seeking stability and income amidst market volatility.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Merck & Co., Inc. (MRK) participated in the Evercore 8th Annual Healthcare Conference, presenting key insights and updates relevant to investors.
Why It Matters
Merck's presentation at the conference can signal strategic plans and insights into their pipeline, potentially impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About MRK Stock
What is Merck & Co., Inc.'s (MRK) stock forecast for 2026?
Based on our analysis of 38 Wall Street analysts, Merck & Co., Inc. (MRK) has a median price target of $105.00. The highest price target is $139.00 and the lowest is $82.00.
Is MRK stock a good investment in 2026?
According to current analyst ratings, MRK has 16 Buy ratings, 13 Hold ratings, and 0 Sell ratings. The stock is currently trading at $99.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRK stock?
Wall Street analysts predict MRK stock could reach $105.00 in the next 12 months. This represents a 5.3% increase from the current price of $99.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Merck & Co., Inc.'s business model?
The company generates revenue through the research, development, production, and marketing of innovative drugs and vaccines for various diseases affecting humans and animals. Key therapeutic areas include oncology, infectious diseases, and diabetes, with a focus on addressing critical health challenges globally.
What is the highest forecasted price for MRK Merck & Co., Inc.?
The highest price target for MRK is $139.00 from Robyn Karnauskas at Truist Securities, which represents a 39.4% increase from the current price of $99.72.
What is the lowest forecasted price for MRK Merck & Co., Inc.?
The lowest price target for MRK is $82.00 from Matthew Harrison at Morgan Stanley, which represents a -17.8% decrease from the current price of $99.72.
What is the overall MRK consensus from analysts for Merck & Co., Inc.?
The overall analyst consensus for MRK is bullish. Out of 38 Wall Street analysts, 16 rate it as Buy, 13 as Hold, and 0 as Sell, with a median price target of $105.00.
How accurate are MRK stock price projections?
Stock price projections, including those for Merck & Co., Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 8, 2025 3:01 PM UTC